Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.3%. By the end of trading, Eli Lilly and Company rose $0.55 (1.1%) to $51.13 on average volume. Throughout the day, 4,245,841 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5,365,400 shares. The stock ranged in a price between $50.66-$51.19 after having opened the day at $50.80 as compared to the previous trading day's close of $50.58. Other companies within the Drugs industry that increased today were: Biostar Pharmaceuticals ( BSPM), up 20.1%, Alcobra ( ADHD), up 15.5%, Epizyme ( EPZM), up 14.3% and Inovio Pharmaceuticals ( INO), up 11.8%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $56.5 billion and is part of the health care sector. Shares are up 2.6% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, increase in net income, largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Biota Pharmaceuticals ( BOTA), down 70.1%, Mast Therapeutics ( MSTX), down 37.2%, Redhill Biopharma ( RDHL), down 20.0% and Oramed Pharmaceuticals ( ORMP), down 10.3% , were all laggards within the drugs industry with Biogen Idec ( BIIB) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices